Bexobrutideg

N/A

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameBexobrutideg
Drug Alias NameNX-5948BTK-IN-24
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionTyrosine-protein kinase BTK degraders
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsCentral Nervous System LymphomaNeurolymphomatosisWaldenstrom Macroglobulinemia +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandNetherlands +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNurix Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNurix Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCentral Nervous System LymphomaNeurolymphomatosisWaldenstrom Macroglobulinemia +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A